Pharmaceuticals

Perrigo

Perrigo released FY2026 Q1 earnings on May 6 Pre-Market (EST), actual revenue USD 969.2 M (forecast USD 1.035 B), actual EPS USD -2.8738 (forecast USD 0.33)

Peregrine Reports Q1 2026 Financials Below Expectations

Perrigo Reports Net Loss and Completes Divestiture

PERRIGO's Q1 EPS Beats Estimates

Perrigo to release FY2026 Q1 earnings on May 6 Pre-Market EST, forecast revenue USD 1.028 B, EPS USD 0.35

Canaccord Analyst Downgrades Perrigo's Target Price to $17, Maintains Buy Rating

Perrigo released FY2025 earnings on February 26 Pre-Market (EST), actual revenue USD 4.253 B (forecast USD 4.24 B), actual EPS USD -10.2916 (forecast USD 0.61)

Perrigo released FY2025 Q4 earnings on February 26 Pre-Market (EST), actual revenue USD 1.11 B (forecast USD 1.092 B), actual EPS USD -10.2242 (forecast USD 0.59)

Perrigo to release FY2025 Q4 earnings on February 26 Pre-Market EST, forecast revenue USD 1.092 B, EPS USD 0.605

Perrigo Director Geoffrey Parker Buys Company Stock

Perrigo Beats Earnings Estimates, But Falls Short on Revenue

Perrigo released FY2025 9 Months earnings on November 5 During-Market EST, actual revenue USD 3.144 B, actual EPS USD -0.0582

Perrigo released FY2025 Q3 earnings on November 5 During-Market (EST), actual revenue USD 1.043 B (forecast USD 1.097 B), actual EPS USD 0.0525 (forecast USD 0.15)

Perrigo to Release FY2025 Q3 Earnings on November 5 During-Market EST, Forecast Revenue USD 1.097 B, EPS USD 0.15

Union 210 Members Approve Three-Year Contract For Perrigo

Abigail Lennox Announces Acquisition of Perrigo Company plc Shares

Perrigo Union Launches Strike In New York

Perrigo released FY2025 Semi-Annual earnings on August 6 During-Market (EST), actual revenue USD 2.1 B, actual EPS USD -0.1072

Perrigo released FY2025 Q2 earnings on August 6 During-Market (EST), actual revenue USD 1.056 B (forecast USD 1.084 B), actual EPS USD -0.0607 (forecast USD 0.04)

Perrick Company Q2 2025 Earnings Report Misses Expectations with $1M Net Loss

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Micware

BiomX

Vida Global

MicroAlgo

MetaVia

Tradr 2X Long XNDU Daily ETF

Ordinary dividend (cash)

Ex Date: 2026.05.29 (EST), Cash dividend 0.29 USD

PRGO

Perrigo Co. PLC (PRGO) shares fell 2.12% to $10.61 on Friday, marking the third consecutive day of losses. The stock is now 62.69% below its 52-week high of $28.44. In comparison, competitors like Johnson & Johnson, Procter & Gamble, and Abbott Laboratories also experienced declines, but to a lesser extent. Trading volume was 2.4 million, below the 50-day average of 3.2 million.

MarketWatch Automated

S&P 500

Dow Jones Industrial Average

Johnson & Johnson

Procter & Gamble

Abbott Laboratories

Factset Research

Perrigo Co. PLC Stock Underperforms Friday When Compared To Competitors

Perrigo Co. PLC (PRGO) shares fell 1.89% to $10.91 on Wednesday, underperforming compared to competitors like Johnson & Johnson, which rose 2.75%. The S&P 500 Index increased by 0.58%, while the Dow Jones Industrial Average decreased by 0.14%. Perrigo's stock is currently 61.63% below its 52-week high of $28.44 reached on July 25. Trading volume was 2.3 million, below the 50-day average of 3.3 million.

Perrigo Co. PLC Stock Underperforms Wednesday When Compared To Competitors

Perrigo Co. PLC (PRGO) shares fell 5.47% to $11.07 on Monday, marking the third consecutive day of losses, despite a positive trading session for the overall market. The stock is currently 61.07% below its 52-week high of $28.44. In comparison, competitors like Johnson & Johnson saw a slight increase, while Procter & Gamble and Abbott Laboratories experienced declines. Trading volume was below the 50-day average.

Perrigo Co. PLC Stock Underperforms Monday When Compared To Competitors

Perrigo Company (PRGO) held its Q1 earnings call, highlighting a mix of operational successes and financial pressures. The company reported market share gains in U.S. store-brand OTC medicines but faced challenges from weaker demand and margin compression. Perrigo's operational enhancements yielded over $7 million in cost savings, with expectations of $60-$80 million by 2026. Despite a decline in CORE net sales by 8.3% year-over-year, management remains optimistic about a recovery in the second half of 2026, reaffirming its full-year guidance. A noncash goodwill impairment of $331 million impacted reported earnings, but cash flow concerns persist.

Tip Ranks

Perrigo Earnings Call Balances Progress and Pressure

Perrigo Co. PLC (PRGO) shares fell 4.40% to $11.72 on Thursday, marking a decline amid a broader market downturn, with the S&P 500 and Dow Jones also dropping. This decline ended a two-day winning streak for Perrigo, which is currently 58.78% below its 52-week high of $28.44. Compared to competitors, Perrigo underperformed, as Johnson & Johnson and Procter & Gamble also saw declines, while Abbott Laboratories experienced a slight increase. Trading volume was below the 50-day average.

Perrigo Co. PLC Stock Underperforms Thursday When Compared To Competitors

Deere & Co. (DE) shares rose 2.75% to $591.64 on a strong trading day, outperforming some competitors. The S&P 500 Index increased by 1.46%, while the Dow Jones Industrial Average rose by 1.24%. Despite the gain, Deere's stock remains 12.24% below its 52-week high of $674.19. Competitors like Caterpillar Inc. (CAT) and CNH Industrial N.V. (CNH) also saw increases, but Deere's trading volume was below its 50-day average.

Deere

Caterpillar

CNH Industrial Nv

Toro

Deere & Co. Stock Outperforms Competitors On Strong Trading Day

Earnings Watch

Perrigo | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 969.2 M

Perrigo Company plc reported its first quarter 2026 financial results, showing a decline in net sales and earnings per share. The company is implementing its Three-S plan to mitigate market challenges and has seen growth in its Specialty Care segment. Following the divestiture of its Dermacosmetics business, Perrigo expects to use the proceeds for debt reduction. Despite a challenging environment, the company maintains its full-year outlook, anticipating improvements in the second half of the year, while monitoring geopolitical impacts and retailer inventory levels.

StockTitan

Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations | PRGO Stock News

Perrigo Company plc (PRGO) reported a significant loss in Q1, with a net loss from continuing operations of $389.8 million, compared to a breakeven profit last year. The decline was attributed to $330.8 million in impairment charges and $75.1 million in restructuring costs. Sales fell 7.2% to $969.2 million, driven by lower consumption in the U.S. and Europe. For the full year, Perrigo expects net sales to decline by 5.5% to 1.5% and adjusted EPS between $2.00 and $2.30.

rttnews

Perrigo Reports A Loss From Cont. Opns. In Q1, Sales Decline

Perrigo(PRGO.US)